Dyne Therapeutics Inc. announced that the Ministry of Health, Labour and Welfare in Japan has granted Orphan Drug designation to zeleciment basivarsen (z-basivarsen) for the treatment of myotonic muscular dystrophy type 1 (DM1). The designation is intended for drugs treating rare diseases affecting fewer than 50,000 patients in Japan and provides benefits such as development cost subsidies and potential market exclusivity for up to 10 years if approved. Z-basivarsen is currently being evaluated in the Phase 1/2 ACHIEVE clinical trial for DM1. The therapy has also received Breakthrough Therapy, Fast Track, and Orphan Drug designations from the U.S. FDA, and Orphan Drug designation from the European Medicines Agency.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Dyne Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9628203-en) on January 20, 2026, and is solely responsible for the information contained therein.